HPV nonavalent vaccination (Gardasil-9) — 3-dose series
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-GARDASIL-9 |
|---|
| ID | REG-HPV-GARDASIL-9 |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-05-18 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-ANAL-2025 SRC-NCCN-CERVICAL-2025 |
Notes
HPV nonavalent vaccine covering HPV-6, 11, 16, 18, 31, 33, 45, 52, 58. 3-dose series (0/2/6 months) for ages 15+. 2-dose series (0/6-12 months) for ages 9-14 — only if first dose received <15yo. >90% efficacy against HPV-attributable pre-cancer and cancer when administered before sexual debut. Catch-up vaccination ages 15-26 routinely recommended; shared-decision-making ages 27-45.
Used By
Access Pathways
AP-GARDASIL-9-OUT-OF-POCKET- HPV-9 vaccine (Gardasil-9) — private pay in Ukraine
Contraindications
CI-GARDASIL-9-PREGNANCY- CI-GARDASIL-9-PREGNANCY
Indication
IND-CHRONIC-HPV-PREVENTION-VACCINATION-SCREENING- IND-CHRONIC-HPV-PREVENTION-VACCINATION-SCREENING